Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Blaine Heck
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q2 (7 quarters).
- Questions
- 11on tracked calls
- Challenge rate
- 9%1 of 11 questions
- Companies
- 2questioned at least once
- Reporting periods
- 7with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 11 of 11 questions from 2 companies
BXPBXP, Inc.6 questions · 6 reporting periods · 1 of 6 challenging
Calendar 2026 Q2
With respect to 343 Madison, can you just elaborate on the appetite you have seen from potential equity partners
Show response
Framed the monetization arc explicitly: developer yield around 8% moving toward a 5.5% to 6% value on delivery.
Calendar 2026 Q1
Is that potentially a source of funds if the transaction market is supportive
Show response
Doug said BXP not looking to exit Kendall Square or Urban Edge life science. Demand shifting to more office and less lab intensity. Signed an LOI for 49K sq ft life science office. Life science market has bottomed with incubator activity improving. Big pharma acquiring Boston-bred life science companies is positive for the ecosystem.
Calendar 2025 Q4
how we should think about the impact of higher concessions associated with the lease-up of the office portfolio
Show response
Mike projected AFFO around $4.40-$4.60 range, slightly above 2025. Less rollover exposure helps despite higher free rent ($130-150M vs prior year). Leasing costs expected at $220-250M, CapEx at $100-125M. AFFO will lag FFO as new leases start in free rent periods, converting to cash in 2027.
Calendar 2025 Q3
your latest thoughts on the New York mayoral race and any sort of impact you've seen
Show response
Owen said negative media coverage is overblown. State controls over transit and taxes provide guardrails. No appetite in Albany for NYC tax increases. Mamdani's potential hire of Jessica Tisch as police chief seen positively. BXP is more constructive than media narrative suggests.
Calendar 2025 Q1
debt to EBITDA ticked up to 8.3x on your numbers this quarter, which is higher than you've run it historically
Show response
Mike explained Q1 seasonality in G&A inflated the metric to 8.3x vs normalized 7.9x. Expects leverage to moderate after 290 Binney delivers mid-2026. Funding from $250M land sales, private equity, and potentially public equity.
Calendar 2024 Q4
whether you've noticed a change in tenants' willingness to move and upgrade their space, given the higher costs to move
Show response
Doug said clients prefer moving to renovating 10+ year old space. Hilary noted confidence in NY driving expansion. Rod noted long-term commitment trend replacing short-term pandemic renewals. Owen cited BXP moving its own offices as proof.
PLDPrologis5 questions · 5 reporting periods · 0 of 5 challenging
Calendar 2026 Q1
given that the occupancy guidance doesn't lead much upside from Q1, is there anything kind of timing related that happened such that where we could see some more downside in Q2 than was initially e...
Show response
Tim acknowledged 20bp occupancy outperformance, explained some was pull-forward from surprise renewals plus strong pipeline giving confidence for remainder.
Calendar 2025 Q4
any thoughts around the strategic capital side of the business and when you might expect to add additional strategies including a potential data center focused fund
Show response
Letter outlined three priorities: extending leadership as best-in-class operator, capturing value creation in logistics and data centers, and growing AUM in strategic capital through existing and new vehicles. Arndt said dialoguing with world's larger investors with very productive couple of months and lot of interest. Capital not the constraint with focus on determining right capital structure. Meaningfully through process expecting to know more in coming weeks and months. Taking care to get right given scale of opportunity. Balance sheet comfortably carrying program which has been very profitable.
Calendar 2025 Q2
are there any specific geographical markets that you think could flip most significantly
Show response
Moghadam said by definition markets with strong long-term fundamentals taking biggest short-term hit like Southern California. Two quarters ago people writing off SoCal. Once couple of deals lost there and goods seen flowing through ports from somewhere other than Kansas FOMO will return. Market will bounce off exaggerated bottom. Caton added secular outperformance in high barrier geographies can really move quickly. International theme outperforming with Europe Latin America and consumption centers like Mexico City and Sao Paulo.
Calendar 2025 Q1
whether you'd expect to see increasing redemption requests in the funds in the coming quarters
Show response
Moghadam said pre-April 2 seeing really strong positive interest with more discussions inquiries and reversing rates than any time since 2022. Post-April 2 people waiting on denominator effect from stock market decline in teens. Institutional over-commitments to private asset classes like venture and PE facing curtailed liquidity from fewer IPOs. Denominator effect will determine how much money comes out not interest in industrial real estate which was good and getting better.
Calendar 2024 Q4
how should we think about the cadence of same-store NOI throughout 2025
Show response
Arndt said lease mark-to-market about 30% at end of 2024 broadly representing the United States including SoCal rent levels. Rent change expected relatively level over quarters so same-store cadence really function of occupancy. Expects some give back on occupancy in next coming quarters followed by rebuild. Lower same-store potentially in front half growing in second half.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| BXP BXP, Inc. | 6 | 17%1 of 6 questions |
| PLD Prologis | 5 | 0%none of 5 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 2 | 0%none of 2 questions | 2 |
| 2025 Q1 | 2 | 50%1 of 2 questions | 2 |
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
| 2025 Q3 | 1 | 0%none of 1 question | 1 |
| 2025 Q4 | 2 | 0%none of 2 questions | 2 |
| 2026 Q1 | 2 | 0%none of 2 questions | 2 |
| 2026 Q2 | 1 | 0%none of 1 question | 1 |
- 2024 Q42 questions · challenge rate 0% (none of 2 questions) · 2 companies
- 2025 Q12 questions · challenge rate 50% (1 of 2 questions) · 2 companies
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q31 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q42 questions · challenge rate 0% (none of 2 questions) · 2 companies
- 2026 Q12 questions · challenge rate 0% (none of 2 questions) · 2 companies
- 2026 Q21 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Capital Allocation5
- Demand2
- Guidance Reliability2
- Margin2
- Macroeconomic2
- Capex Investment1
- Innovation & R&D1
- Revenue Growth1
- Cloud & AI1
- Regulation Policy1
Show all 14 topics
- Geographic Expansion1
- Pricing1
- Credit1
- Cost Pressure1